#AM25IMPACT
LightNews LightNews
onclive.bsky.social
Good morning Seattle! 🌆

☔ Rain or shine, we're ready to kick off our live coverage of #SGO2025! From expert-led sessions to cutting-edge research, we’ll be sharing all the latest updates in gynecologic oncology. You won't want to miss it!

#SGOMtg #AM25IMPACT #gynsm
March 15, 2025 at 1:30 PM
onclive.bsky.social
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer #SGOMtg #AM25IMPACT #SGO2025 www.onclive.com/view/olapari...
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer
Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.
www.onclive.com
March 15, 2025 at 4:53 PM
onclive.bsky.social
Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer #SGOMtg #AM25IMPACT #SGO2025 #ovca #gyncsm www.onclive.com/view/updated...
Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine continued to showcase superior OS, PFS, ORR, & DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.
www.onclive.com
March 16, 2025 at 5:11 PM
onclive.bsky.social
Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer #SGOMtg #AM25IMPACT #SGO2025 #gyncsm www.onclive.com/view/nivolum...
Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer
Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients experienced disease recurrence during follow-up.
www.onclive.com
March 15, 2025 at 3:25 PM
sitemancenter.bsky.social
#SGOmtg: @washumedicine.bsky.social gynecologic oncologist and surgeon Lindsay Kuroki, MD, presents today. #SGOMtg #AM25IMPACT

Check out the conference details here: bit.ly/4ioTbE8
March 17, 2025 at 1:55 PM
sitemancenter.bsky.social
#SGOmtg: @washumedicine.bsky.social gynecologic oncologist and surgeon Matthew A. Powell, MD, presents today. #SGOMtg #AM25IMPACT

Check out the conference details here: bit.ly/4ioTbE8
March 15, 2025 at 8:20 PM
sitemancenter.bsky.social
The Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer takes place this weekend, featuring presentations by @washumedicine.bsky.social physicians Matthew Powell, MD, and Lindsay Kuroki, MD. #SGOMtg #AM25IMPACT #SGO2025

Learn more: bit.ly/4hsHDOR
March 13, 2025 at 9:25 PM
researchmatters.bsky.social
Who will be at #SGOMtg? I'm speaking at the Patient Advocate Panel on March 14 about how I've become an accidental advocate (but a committed one!)
#AM25IMPACT
March 12, 2025 at 12:12 AM
onclive.bsky.social
Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/pamipar...
Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer
Pamiparib plus surufatinib showed signals of activity with a largely hematologic adverse effect profile in patients with PARP-pretreated, platinum-resistant ovarian cancer.
www.onclive.com
March 17, 2025 at 9:42 PM
onclive.bsky.social
Metformin With IUD Boosts Responses in EIN and Endometrial Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/metform...
Metformin With IUD Boosts Responses in EIN and Endometrial Cancer
Patients with endometrial cancer had slightly higher CR rates with metformin plus a levonorgestrel-releasing IUD vs historical data with the IUD alone.
www.onclive.com
March 17, 2025 at 3:59 PM
onclive.bsky.social
Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer #SGOMtg #AM25IMPACT #SGO2025 #oncology #gyncsm
www.onclive.com/view/zimbere...
Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer
The combination of zimberelimab and lenvatinib had antitumor activity and a manageable safety profile in pretreated advanced cervical cancer.
www.onclive.com
March 15, 2025 at 8:17 PM
onclive.bsky.social
Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer #SGOMtg #AM25IMPACT #SGO2025 #gyncsm #oncology
www.onclive.com/view/afurese...
Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer
Afuresertib combined with paclitaxel did not elicit PFS or OS benefits vs paclitaxel alone in patients with unselected platinum-resistant ovarian cancer.
www.onclive.com
March 15, 2025 at 8:12 PM
onclive.bsky.social
Pembrolizumab Plus Concurrent Chemoradiotherapy Improves OS, PFS2 in Advanced Cervical Cancer @uvahealth.bsky.social #SGOMtg #AM25IMPACT #SGO2025 #gyncsm www.onclive.com/view/pembrol...
Pembrolizumab Plus Concurrent Chemoradiotherapy Improves OS, PFS2 in Advanced Cervical Cancer
The addition of pembrolizumab to chemoradiotherapy prolonged survival and time to second progression in patients with locally advanced cervical cancer.
www.onclive.com
March 15, 2025 at 4:29 PM
onclive.bsky.social
Cadonilimab Plus Lenvatinib Proves Active in Platinum-Pretreated, Advanced Endometrial Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/cadonil...
Cadonilimab Plus Lenvatinib Proves Active in Platinum-Pretreated, Advanced Endometrial Cancer
Cadonilimab plus lenvatinib showed promise as therapy for patients with advanced endometrial cancer and disease progression on prior platinum therapy.
www.onclive.com
March 15, 2025 at 3:35 PM